Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 17, Issue 9, pp. 1893-1901
PubMed
Published By
Print ISSN
Online ISSN
History
- Received July 18, 2017
- Revision received October 24, 2017
- Accepted June 25, 2018
- Published first July 3, 2018.
Article Versions
- Previous version (July 3, 2018 - 06:38).
- Previous version (August 9, 2018 - 07:03).
- You are viewing the most recent version of this article.
Copyright & Usage
©2018 American Association for Cancer Research.
Author Information
- Minjee Kim1,
- Daniel J. Ma2,
- David Calligaris3,4,
- Shuangling Zhang1,
- Ryan W. Feathers5,
- Rachael A. Vaubel2,
- Isabelle Meaux6,
- Ann C. Mladek2,
- Karen E. Parrish1,
- Fang Jin2,
- Cedric Barriere6,
- Laurent Debussche6,
- James Watters6,
- Shulan Tian2,
- Paul A Decker2,
- Jeanette E. Eckel-Passow2,
- Gaspar J. Kitange2,
- Aaron J. Johnson2,
- Ian F. Parney2,
- Panos Z. Anastasiadis5,
- Nathalie Y.R. Agar3,4,7,
- William F. Elmquist1, and
- Jann N. Sarkaria2,*
- 1University of Minnesota, Minneapolis, Minnesota.
- 2Mayo Clinic, Rochester, Minnesota.
- 3Brigham and Women's Hospital, Boston, Massachusetts.
- 4Harvard Medical School, Boston, Massachusetts.
- 5Mayo Clinic, Jacksonville, Florida.
- 6Sanofi Oncology, Vitry-sur-Seine, France.
- 7Dana Farber Cancer Institute, Boston, Massachusetts.
- ↵*Corresponding Author:
Jann N. Sarkaria, 200 First Street, SW, Rochester, MN 55905. Phone: 507-284-9025; Fax: 507-284-3906; E-mail: Sarkaria.jann{at}mayo.edu
M. Kim and D.J. Ma contributed equally to this article.
September 2018
Volume 17, Issue 9
Volume 17, Issue 9
Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier
Jump to section
Advertisement